NanoViricides (NNVC) News Today $1.32 -0.05 (-3.65%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NanoViricides pushes NV-387 to Phase II trialsNovember 15, 2024 | proactiveinvestors.comNanoViricides (NYSE:NNVC) Stock Rating Lowered by StockNews.comNovember 11, 2024 | americanbankingnews.comNanoViricides Inc. (NNVC): Best Nanotech Penny Stock to BuyOctober 14, 2024 | msn.comInvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR SummitOctober 8, 2024 | msn.comNanoViricides prepares for Phase II trials for antiviral NV-387September 30, 2024 | proactiveinvestors.comNanoviricides (AMEX:NNVC) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comNanoViricides expands antiviral drug pipeline with TheraCour Pharma agreementSeptember 26, 2024 | proactiveinvestors.comNanoViricides CEO talks lead drug asset's potential as MPOX therapy - ICYMISeptember 14, 2024 | proactiveinvestors.comNanoViricides exploring emergency protocol to evaluate NV-387 for MPOXAugust 26, 2024 | proactiveinvestors.comNanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387August 19, 2024 | proactiveinvestors.comNanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387August 8, 2024 | proactiveinvestors.comFrontier Biotechnologies Inc. (688221.SS)August 8, 2024 | finance.yahoo.comNanoViricides' lead asset for broad spectrum efficacy wins praise in industry reportsAugust 1, 2024 | proactiveinvestors.comNNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral TherapyJuly 31, 2024 | msn.comNanoViricides spotlights lead drug candidate's potential as COVID therapyJuly 24, 2024 | proactiveinvestors.comNanoViricides discusses lead program and next stepsJuly 11, 2024 | proactiveinvestors.comNanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trialJuly 1, 2024 | proactiveinvestors.comNanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1June 24, 2024 | proactiveinvestors.comNanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza AJune 20, 2024 | proactiveinvestors.comNanoViricides antiviral candidate 'may be first effective oral nanomedicine'June 11, 2024 | proactiveinvestors.comNanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosingJune 4, 2024 | proactiveinvestors.comA First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and MoreMay 29, 2024 | finance.yahoo.comNanoViricides CEO says lead asset NV-387 could be ‘holy grail' of antiviral medicinesMay 29, 2024 | proactiveinvestors.comNanoViricides taps Aagami to seek out licensing and partnership opportunitiesMay 23, 2024 | proactiveinvestors.comNanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.May 23, 2024 | finance.yahoo.comNanoViricides could generate ‘antiviral superdrug' for multiple diseases, analysts believeMay 21, 2024 | proactiveinvestors.comNanoViricides, Inc.: Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential CureMay 20, 2024 | finanznachrichten.deNanoViricides reports strong antiviral activity of NV-387 against RSVMay 20, 2024 | proactiveinvestors.comNanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo FinanceMay 19, 2024 | finance.yahoo.comNanoViricides unveils new data showing lead drug asset's strong activity against RSVMay 14, 2024 | proactiveinvestors.comA Novel Broad-Spectrum Antiviral with Activity Against RSVMay 14, 2024 | finance.yahoo.comNanoViricides CEO discusses NV-387's broad-spectrum antiviral potentialMay 13, 2024 | proactiveinvestors.comNanoViricides to showcase lead drug asset's progress at EF Hutton Annual Global ConferenceMay 10, 2024 | proactiveinvestors.comNanoViricides, Inc.: NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York CityMay 10, 2024 | finanznachrichten.deNanoViricides says lead asset shows antiviral activity against Smallpox and MpoxMay 8, 2024 | proactiveinvestors.comNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/MpoxMay 8, 2024 | finanznachrichten.deNanoViricides, Inc. (NNVC)May 8, 2024 | finance.yahoo.comNanoViricides drug asset shows ‘superior antiviral effects’ against Influenza AMay 6, 2024 | ca.investing.comNanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare moversMay 6, 2024 | msn.comNanoViricides drug asset shows ‘superior antiviral effects' against Influenza AMay 6, 2024 | proactiveinvestors.comNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Influenza AMay 6, 2024 | finanznachrichten.deNanoViricides completes Phase 1 trial of lead asset NV-387April 30, 2024 | proactiveinvestors.comNanoviricides Stock (AMEX:NNVC) Earnings Dates and Earning CallsFebruary 26, 2024 | benzinga.comNanoViricides boosts liquidity measures and manufacturing capacity to support clinical trialsFebruary 15, 2024 | proactiveinvestors.comNanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the HorizonFebruary 15, 2024 | finance.yahoo.comA New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?February 1, 2024 | benzinga.comClinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as AntibioticsFebruary 1, 2024 | finance.yahoo.comNanoViricides successfully concludes first-in-human studyJanuary 29, 2024 | proactiveinvestors.comNanoViricides makes progress as it completes dosing in Phase 1a COVID studyJanuary 29, 2024 | proactiveinvestors.comSafety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events FoundJanuary 29, 2024 | finance.yahoo.com Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. NNVC Media Mentions By Week NNVC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NNVC News Sentiment▼0.330.45▲Average Medical News Sentiment NNVC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NNVC Articles This Week▼11▲NNVC Articles Average Week Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PDS Biotechnology News Werewolf Therapeutics News Vistagen Therapeutics News Ovid Therapeutics News BioAtla News Leap Therapeutics News CytomX Therapeutics News BeyondSpring News Cellectar Biosciences News AlloVir News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NNVC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
